Foundation News

NEW YORK, NY – The cost of care for inflammatory bowel disease (IBD) in the United States has increased significantly over the past five years, according to the results of the Crohn’s & Colitis Foundation’s cost of care study.

NEW YORK, NY – Today, the Crohn’s & Colitis Foundation released its new five-year research agenda to address unmet needs in the inflammatory bowel disease (IBD) research community and provide a roadmap for not only the Foundation but also the IBD research community at-large.

Ever wanted to own a pair of NFL cleats? Well now you can! Jordan Wilkins of the Indianapolis Colts has generously donated a pair of cleats and a helmet that he's autographed. Click here to bid on them today!

We hope you're excited for all the upcoming events we're planning in Wisconsin this year!

New York, New York – The American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), and the Crohn’s & Colitis Foundation (Foundation), in partnership with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address vaccine utilizati

New York, New York – The Crohn’s & Colitis Foundation is launching a new open access journal to engage, inform, and catalyze dialogue on state-of-the-art, comprehensive care for the millions ofAmericans living with inflammatory bowel diseases (IBD).

CAMBRIDGE, England—PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced details of a jointly sponsored study with the US Crohn’s & Colitis Foundation.

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel disease (IBD), which may affect as many as 1 in 100 Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.